AR035516A1 - Sulfonamidas heterociclicas y el uso de las mismas para la preparacion de medicamentos que inhiben la produccion de amiloides beta - Google Patents
Sulfonamidas heterociclicas y el uso de las mismas para la preparacion de medicamentos que inhiben la produccion de amiloides betaInfo
- Publication number
- AR035516A1 AR035516A1 ARP010105782A ARP010105782A AR035516A1 AR 035516 A1 AR035516 A1 AR 035516A1 AR P010105782 A ARP010105782 A AR P010105782A AR P010105782 A ARP010105782 A AR P010105782A AR 035516 A1 AR035516 A1 AR 035516A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- group
- phenyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Una sulfonamida heterocíclica, que comprende un compuesto de la fórmula (1), o una sal de dicha fórmula farmacéuticamente aceptable, donde: R1 y R2 se escogen en forma independiente del grupo compuesto por hidrógeno, alquilo, alquilo sustituido, CF3, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, cicloalquilo, cicloalquilo sustituido, fenilo, fenilo sustituido, y (CH2)n(1,3)dioxano, donde el valor de n es de 2 a 5; R3 se escoge del grupo compuesto por hidrógeno, alquilo, y alquilo sustituido; R4 se escoge del grupo compuesto por hidrógeno, alquilo, alquilo sustituido, alquilcicloalquilo, alquilcicloalquilo sustituido, fenil alquilo (sustituido), alquilOH, alquilOH sustituido, alquilObencilo, alquilObencilo sustituido, alquilpiridilo, alquilpiridilo sustituido, alquilfuranilo, alquilfuranilo sustituido, CH(OH)fenilo, CH(OH)fenilo sustituido, alquenilo, alquenilo sustituido, cicloalquilo, cicloalquilo sustituido, piperidinilo N-sustituido, piperidinilo, piperidinilo sustituido, tetrahidrotiopirano, tetrahidrotiopirano sustituido, 2-indano, 2-indano sustituido, fenilo, fenilo sustituido, alquilNHR7, y alquilNHR7 sustituido; con la salvedad de que R3 y R4 no son hidrógeno;R7 es alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, bencilo, bencilo sustituido, alquilOH, alquilOH sustituido, alquilSR8, o alquilSR8 sustituido; R8 es alquilo, alquilo sustituido, bencilo, o bencilo sustituido; o R3 y R4 se pueden unir para formar un anillo; R5 se escoge del grupo compuesto por hidrógeno, alquilo inferior, alquilo inferior sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, CH2cicloalquilo, CH2cicloalquilo sustituido, bencilo, bencilo sustituido, y CH2CH2QR9; Q es O, NH ó S; R9 es alquilo inferior, alquilo inferior sustituido, fenilo, o fenilo sustituido; R6 se escoge del grupo compuesto por hidrógeno, halógeno y CF3; T se escoge del grupo compuesto por los restos de fórmulas (2), (3) y (4); W, Y y Z se escogen en forma independiente del grupo compuesto por C, CR10 y N; R10 se escoge del grupo compuesto por hidrógeno y halógeno, con la salvedad de que por lo menos uno, W, Y o Z, debe ser C; X se escoge del grupo compuesto por O, S, SO2, y NR11; R11 se escoge del grupo compuesto por hidrógeno, alquilo inferior, alquilo inferior sustituido, bencilo, bencilo sustituido, fenilo, y fenilo sustituido; siempre que cuando el compuesto contenga uno o más centros quirales, por lo menos uno de esos centros quirales tenga estereoquímica S. Se describen además el uso de estas sulfonamidas heterocíclicas para preparar medicamentos para inhibir la producción de beta amiloides y para el tratamiento de la Enfermedad de Alzheimer y el Síndrome de Down, angiopatía amiloide, angiopatía amiloide cerebral, amiloidosis sistémica, hemorragia cerebral hereditaria con amiloidosis del tipo holandés, y miositis de cuerpos de inclusión.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25510500P | 2000-12-13 | 2000-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035516A1 true AR035516A1 (es) | 2004-06-02 |
Family
ID=22966854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010105782A AR035516A1 (es) | 2000-12-13 | 2001-12-12 | Sulfonamidas heterociclicas y el uso de las mismas para la preparacion de medicamentos que inhiben la produccion de amiloides beta |
Country Status (28)
Country | Link |
---|---|
US (5) | US6610734B2 (es) |
EP (1) | EP1341779B1 (es) |
JP (2) | JP2004517892A (es) |
KR (1) | KR100869061B1 (es) |
CN (2) | CN1800176A (es) |
AR (1) | AR035516A1 (es) |
AT (1) | ATE330950T1 (es) |
AU (1) | AU2002245123B2 (es) |
BR (1) | BR0116063A (es) |
CA (1) | CA2436526C (es) |
CY (1) | CY1105441T1 (es) |
DE (1) | DE60121032T2 (es) |
DK (1) | DK1341779T3 (es) |
EA (1) | EA009035B1 (es) |
ES (1) | ES2267853T3 (es) |
HK (1) | HK1059619A1 (es) |
HU (1) | HUP0303857A3 (es) |
IL (3) | IL156268A0 (es) |
MX (1) | MXPA03005255A (es) |
NO (1) | NO328885B1 (es) |
NZ (2) | NZ538100A (es) |
PL (1) | PL365950A1 (es) |
PT (1) | PT1341779E (es) |
SG (1) | SG128491A1 (es) |
SI (1) | SI1341779T1 (es) |
TW (1) | TWI235155B (es) |
WO (1) | WO2002057252A2 (es) |
ZA (1) | ZA200304135B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001240861B2 (en) * | 2000-03-20 | 2006-03-30 | Merck Frosst Canada Ltd | Sulphonamido-substituted bridged bicycloalkyl derivatives |
MXPA03005255A (es) | 2000-12-13 | 2004-10-14 | Wyeth Corp | Inhibidores de produccion de beta-amiloide de sulfonamida heterociclica. |
US6657070B2 (en) | 2000-12-13 | 2003-12-02 | Wyeth | Production of chirally pure α-amino acids and N-sulfonyl α-amino acids |
KR100921641B1 (ko) * | 2001-12-11 | 2009-10-14 | 와이어쓰 | 순수한 키랄성 β-아미노 알콜의 합성방법 |
BR0311767A (pt) * | 2002-06-11 | 2005-03-08 | Wyeth Corp | Compostos inibidores de sulfonamida substituìda da produção de beta amilóide, suas composições e usos |
CA2505098A1 (en) | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
NZ542468A (en) * | 2003-03-31 | 2009-01-31 | Wyeth Corp | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof |
KR20060066057A (ko) * | 2003-06-30 | 2006-06-15 | 다이이찌 세이야꾸 가부시기가이샤 | 복소환 메틸 설폰 유도체 |
WO2005073198A1 (en) | 2004-01-16 | 2005-08-11 | Wyeth | Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole |
CA2595173A1 (en) | 2005-01-18 | 2006-07-27 | Elan Pharmaceuticals, Inc. | N-substituted heterocyclic sulfonamides |
EP2457901A1 (en) * | 2005-03-14 | 2012-05-30 | High Point Pharmaceuticals, LLC | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
GB0602951D0 (en) * | 2006-02-14 | 2006-03-29 | Novartis Ag | Organic Compounds |
EP1984347A1 (en) * | 2006-02-17 | 2008-10-29 | Wyeth a Corporation of the State of Delaware | Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols |
AR059518A1 (es) * | 2006-02-17 | 2008-04-09 | Wyeth Corp | Metodos para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios |
US7476762B2 (en) * | 2006-04-21 | 2009-01-13 | Wyeth | Methods for preparing sulfonamide compounds |
US7550629B2 (en) * | 2006-04-21 | 2009-06-23 | Wyeth | Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors |
JP2009534385A (ja) * | 2006-04-21 | 2009-09-24 | ワイス | キラル的に純粋なアミノアルコール中間体、それらの誘導体の製造、及びそれらの使用 |
TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
WO2008059238A1 (en) * | 2006-11-17 | 2008-05-22 | Astrazeneca Ab | Benzenesulfonamide compounds as edg-1 antagonists useful in the treatment of cancer |
WO2008064320A2 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
US20080262228A1 (en) * | 2006-11-28 | 2008-10-23 | Wyeth | Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof |
TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
AU2008215948A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of AD and related conditions |
PE20090445A1 (es) * | 2007-07-16 | 2009-05-18 | Wyeth Corp | Inhibidores de produccion de beta amiloide |
PA8789801A1 (es) * | 2007-07-16 | 2009-02-09 | Wyeth Corp | Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica |
PE20090824A1 (es) * | 2007-07-16 | 2009-07-24 | Wyeth Corp | Proceso para la preparacion de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterociclicas |
US8354446B2 (en) | 2007-12-21 | 2013-01-15 | Ligand Pharmaceuticals Incorporated | Selective androgen receptor modulators (SARMs) and uses thereof |
US20090181932A1 (en) * | 2008-01-11 | 2009-07-16 | Wyeth | COMPOSITIONS CONTAINING O-SULFATE AND O-PHOSPHATE CONTAINING ARYL SULFONAMIDE DERIVATIVES USEFUL AS beta-AMYLOID INHIBITORS |
US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
EP3586839A1 (en) | 2008-07-28 | 2020-01-01 | Blanchette Rockefeller Neurosciences, Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
KR20120096076A (ko) | 2009-12-17 | 2012-08-29 | 메르크 파텐트 게엠베하 | 스핑고신 키나아제 저해제 |
US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
TWI686193B (zh) | 2013-01-18 | 2020-03-01 | 美商卡爾迪奧克斯爾製藥公司 | 具有增進之治療指數的硝醯基予體 |
CN104370769B (zh) * | 2013-08-14 | 2017-05-31 | 重庆博腾制药科技股份有限公司 | 一种制备羟基金刚烷甘氨酸衍生物的方法 |
EP3613418A1 (en) | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
WO2017155890A1 (en) * | 2016-03-11 | 2017-09-14 | Ohio State Innovation Foundation | Novel small molecule antimicrobials |
DE202022106287U1 (de) | 2022-11-09 | 2022-11-21 | Ahmad Salawi | Eine Methode zur Synthese und biologischen Bewertung von neuen Sulfonamid-Analoga |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US656536A (en) * | 1899-12-28 | 1900-08-21 | David Fitzgibbons | Boiler. |
US3376523A (en) * | 1966-12-27 | 1968-04-02 | Univ California | Transient-suppressing magnetic transmission line |
US5594021A (en) | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5571821A (en) | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5514691A (en) | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5464853A (en) | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US5591761A (en) | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
EP0510700A3 (en) | 1991-04-26 | 1992-12-16 | Takeda Chemical Industries, Ltd. | Azole compounds, their production and use |
GB9110722D0 (en) | 1991-05-17 | 1991-07-10 | Fujisawa Pharmaceutical Co | Amine derivatives |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
JP3599287B2 (ja) * | 1993-04-28 | 2004-12-08 | 三菱化学株式会社 | スルホンアミド誘導体 |
US6342610B2 (en) * | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
CZ184194A3 (en) | 1993-08-09 | 1995-03-15 | Lilly Co Eli | Aspartylprotease inhibitor and method of identifying thereof |
US5519040A (en) | 1994-04-29 | 1996-05-21 | Allergan | Substituted thiazole sulfonamides as antiglaucoma agents |
US5561146A (en) * | 1994-06-10 | 1996-10-01 | Bristol-Myers Squibb Company | Modified guanidino and amidino thrombin inhibitors |
US5624937A (en) | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
EP0761680A3 (en) * | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
JPH09136878A (ja) * | 1995-09-12 | 1997-05-27 | Ono Pharmaceut Co Ltd | テトラゾール誘導体 |
ATE377006T1 (de) * | 1995-11-28 | 2007-11-15 | Cephalon Inc | Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer |
AU1209497A (en) | 1995-12-27 | 1997-07-28 | Takeda Chemical Industries Ltd. | Oxazole derivatives, their production and use |
JPH09235276A (ja) * | 1995-12-27 | 1997-09-09 | Takeda Chem Ind Ltd | オキサゾール誘導体、その製造法および用途 |
US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
CZ16899A3 (cs) | 1996-07-22 | 1999-08-11 | Monsanto Company | Thiolsulfonamidové inhibitory metaloproteázy |
US5703129A (en) | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
KR20000049050A (ko) * | 1996-10-11 | 2000-07-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 술폰아미드 치환된 아스파르트산 인터루킨-1β 전환 효소 억제제 |
US5985930A (en) | 1996-11-21 | 1999-11-16 | Pasinetti; Giulio M. | Treatment of neurodegenerative conditions with nimesulide |
HUP0001383A3 (en) | 1996-11-22 | 2001-11-28 | Lilly Co Eli | N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same and their use |
DE19650196A1 (de) * | 1996-12-04 | 1998-06-10 | Bayer Ag | Thienylsulfonylamino(thio)carbonylverbindungen |
GB9725138D0 (en) * | 1997-11-27 | 1998-01-28 | Pharmacia & Upjohn Spa | Thiophenesulfonamide compounds |
JPH11343279A (ja) | 1998-03-16 | 1999-12-14 | Shionogi & Co Ltd | スルホンアミド誘導体およびそれらを含有するTNF―α産生抑制剤 |
US5981168A (en) | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
AU1708099A (en) * | 1998-06-03 | 1999-12-20 | Amgen, Inc. | N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres |
US7410995B1 (en) | 1998-08-14 | 2008-08-12 | Gpi Nil Holdings Inc. | N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders |
MXPA01008606A (es) | 1999-02-26 | 2003-05-05 | Merck & Co Inc | Compuestos de sulfonamida novedosos y uso de los mismos. |
US6495578B1 (en) | 1999-04-19 | 2002-12-17 | Shionogi & Co., Ltd. | Sulfonamide derivatives having oxadiazole rings |
EP1088815A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl amino acid derivatives |
EP1088821A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
AU7997700A (en) * | 1999-10-08 | 2001-04-23 | Du Pont Pharmaceuticals Company | Amino lactam sulfonamides as inhibitors of abeta protein production |
MXPA03005255A (es) | 2000-12-13 | 2004-10-14 | Wyeth Corp | Inhibidores de produccion de beta-amiloide de sulfonamida heterociclica. |
US6657070B2 (en) | 2000-12-13 | 2003-12-02 | Wyeth | Production of chirally pure α-amino acids and N-sulfonyl α-amino acids |
EP1461332A4 (en) | 2001-12-11 | 2009-10-21 | Wyeth Corp | PRODUCTION OF ALPHA-AMINO ACIDS AND CHIRALLY PURE ALPHA-AMINO N-SULFONYL ACIDS |
KR100921641B1 (ko) | 2001-12-11 | 2009-10-14 | 와이어쓰 | 순수한 키랄성 β-아미노 알콜의 합성방법 |
BR0311767A (pt) | 2002-06-11 | 2005-03-08 | Wyeth Corp | Compostos inibidores de sulfonamida substituìda da produção de beta amilóide, suas composições e usos |
NZ542468A (en) * | 2003-03-31 | 2009-01-31 | Wyeth Corp | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof |
-
2001
- 2001-12-11 MX MXPA03005255A patent/MXPA03005255A/es active IP Right Grant
- 2001-12-11 EP EP01993277A patent/EP1341779B1/en not_active Expired - Lifetime
- 2001-12-11 BR BR0116063-0A patent/BR0116063A/pt not_active Application Discontinuation
- 2001-12-11 CN CNA2005100035919A patent/CN1800176A/zh active Pending
- 2001-12-11 NZ NZ538100A patent/NZ538100A/en unknown
- 2001-12-11 KR KR1020037007928A patent/KR100869061B1/ko not_active IP Right Cessation
- 2001-12-11 DK DK01993277T patent/DK1341779T3/da active
- 2001-12-11 PT PT01993277T patent/PT1341779E/pt unknown
- 2001-12-11 IL IL15626801A patent/IL156268A0/xx active IP Right Review Request
- 2001-12-11 ES ES01993277T patent/ES2267853T3/es not_active Expired - Lifetime
- 2001-12-11 DE DE60121032T patent/DE60121032T2/de not_active Expired - Lifetime
- 2001-12-11 WO PCT/US2001/048375 patent/WO2002057252A2/en active Application Filing
- 2001-12-11 NZ NZ526213A patent/NZ526213A/en unknown
- 2001-12-11 US US10/014,304 patent/US6610734B2/en not_active Expired - Fee Related
- 2001-12-11 EA EA200300674A patent/EA009035B1/ru not_active IP Right Cessation
- 2001-12-11 JP JP2002557933A patent/JP2004517892A/ja not_active Withdrawn
- 2001-12-11 SI SI200130604T patent/SI1341779T1/sl unknown
- 2001-12-11 CN CNB018205186A patent/CN1263750C/zh not_active Expired - Fee Related
- 2001-12-11 CA CA2436526A patent/CA2436526C/en not_active Expired - Fee Related
- 2001-12-11 SG SG200503628A patent/SG128491A1/en unknown
- 2001-12-11 HU HU0303857A patent/HUP0303857A3/hu unknown
- 2001-12-11 PL PL01365950A patent/PL365950A1/xx not_active IP Right Cessation
- 2001-12-11 AT AT01993277T patent/ATE330950T1/de active
- 2001-12-11 AU AU2002245123A patent/AU2002245123B2/en not_active Ceased
- 2001-12-12 TW TW090130721A patent/TWI235155B/zh active
- 2001-12-12 AR ARP010105782A patent/AR035516A1/es not_active Application Discontinuation
-
2003
- 2003-05-28 ZA ZA200304135A patent/ZA200304135B/en unknown
- 2003-06-02 IL IL156268A patent/IL156268A/en not_active IP Right Cessation
- 2003-06-05 US US10/455,674 patent/US6878742B2/en not_active Expired - Fee Related
- 2003-06-11 NO NO20032645A patent/NO328885B1/no not_active IP Right Cessation
-
2004
- 2004-03-02 HK HK04101538A patent/HK1059619A1/xx not_active IP Right Cessation
-
2005
- 2005-03-16 US US11/081,784 patent/US7691884B2/en not_active Expired - Fee Related
-
2006
- 2006-09-14 CY CY20061101305T patent/CY1105441T1/el unknown
-
2008
- 2008-01-17 IL IL188853A patent/IL188853A0/en unknown
-
2009
- 2009-10-09 US US12/576,513 patent/US7842718B2/en not_active Expired - Fee Related
-
2010
- 2010-06-24 JP JP2010144307A patent/JP2010265280A/ja not_active Withdrawn
- 2010-10-19 US US12/907,123 patent/US20110034513A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035516A1 (es) | Sulfonamidas heterociclicas y el uso de las mismas para la preparacion de medicamentos que inhiben la produccion de amiloides beta | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
AR042423A1 (es) | Diaril eteres como antagonistas del receptor opioide | |
AR049398A1 (es) | Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados. | |
AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
AR010378A1 (es) | Novedosos compuestos con efecto analgesico, uso de los mismos para la preparacion de un medicamento y como agente de diagnostico, composicion farmaceutica, proceso para la preparacion de dichos compuestos y compuestos intermediarios | |
CO4900063A1 (es) | Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2 | |
AR035260A1 (es) | Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer | |
AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
AR051469A1 (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
DOP2006000063A (es) | Derivados de ciclopropanocarboxamida | |
AR072545A1 (es) | Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
AR032072A1 (es) | Derivados de quinuclidina novedosos y composiciones medicinales que los contienen | |
AR032621A1 (es) | Compuestos derivados de tiofeno, metodo para su preparacion, composicion farmaceutica y uso en la fabricacion de medicamentos | |
AR045931A1 (es) | Derivados de piperazina | |
CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
AR048808A1 (es) | Pirrolocarbazoles fusionados | |
AR067904A1 (es) | Derivados de piperazina-amida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal | ||
FB | Suspension of granting procedure |